A Single Missense Mutation in 77% of Prostate Cancer Bone Metastases: Novel Opportunity for Genetic Biomarker and Novel Therapeutic Mitochondrial Target
Technical Report,30 Sep 2016,29 Sep 2017
Emory University Atlanta United States
Pagination or Media Count:
The purpose of this project is to determine the frequency of a mitochondrial DNA mutation at nucleotide position 10398 in the ND3 gene in prostate cancer tissues and metastases, especially bone metastases and to perform experiments in mice to determine whether the observed mutation enables or enhances bone metastases and the lethal phenotype of prostate cancer. The major findings to date are that over 50 of an expanded cohort of patients do indeed harbor the mutation in a bone-metastasis-specific fashion. Mechanistic studies in cell lines and mice are in progress with no conclusions at this early point in the project. The results to date are significant and may have broad applicability to the influence of the mitochondrial genome to cancer phenotype, especially metastasis. The model systems underdevelopment may allow mechanism to be determined.
- Medicine and Medical Research